Literature DB >> 17654359

Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam.

Lindsay E Nicolle1, Michael R Mulvey.   

Abstract

Oral therapy options for pyelonephritis caused by ESBL producing E. coli are limited. We describe a woman with relapsing pyelonephritis due to a CTX-M ESBL E. coli who was cured with a prolonged course of pivmecillinam. This suggests pivmecillinam may be effective treatment for selected patients with pyelonephritis with these organisms.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17654359     DOI： 10.1080/00365540701367801

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN： 0036-5548


  9 in total

Review 1.  Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Souha S Kanj; Zeina A Kanafani
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

Review 2.  Clinical management of infections caused by multidrug-resistant Enterobacteriaceae.

Authors:  Mercedes Delgado-Valverde; Jesús Sojo-Dorado; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Ther Adv Infect Dis       Date:  2013-04

3.  Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production.

Authors:  N T Mutters; S Zimmermann; M Kaase; A Mischnik
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-10-03       Impact factor: 3.267

4.  Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

Authors:  Simon Auer; Alexandra Wojna; Markus Hell
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

5.  In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli.

Authors:  M Tärnberg; A Ostholm-Balkhed; H-J Monstein; A Hällgren; H Hanberger; L E Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-06       Impact factor: 3.267

Review 6.  Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices.

Authors:  Johann D D Pitout
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

7.  High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.

Authors:  Arne Søraas; Arnfinn Sundsfjord; Silje Bakken Jørgensen; Knut Liestøl; Pål A Jenum
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

Review 8.  A new strategy to fight antimicrobial resistance: the revival of old antibiotics.

Authors:  Nadim Cassir; Jean-Marc Rolain; Philippe Brouqui
Journal:  Front Microbiol       Date:  2014-10-20       Impact factor: 5.640

Review 9.  Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review.

Authors:  Filip Jansåker; Niels Frimodt-Møller; Thomas L Benfield; Jenny Dahl Knudsen
Journal:  Infect Drug Resist       Date:  2018-05-24       Impact factor: 4.003
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.